{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T13:04:48Z","timestamp":1793883888240,"version":"4.7.0"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychiatric Research"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.jpsychires.2020.02.022","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T23:30:42Z","timestamp":1582759842000},"page":"109-114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["Duloxetine and cardiovascular adverse events: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"124","author":[{"given":"Kyounghoon","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonji","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young-Jin","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byung-Joo","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychires.2020.02.022_bib1","author":"Agency for Healthcare Research and Quality"},{"issue":"4","key":"10.1016\/j.jpsychires.2020.02.022_bib2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1177\/0269881108091588","article-title":"A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder","volume":"22","author":"Allgulander","year":"2008","journal-title":"J. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.jpsychires.2020.02.022_bib3","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.pain.2005.06.031","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder","volume":"119","author":"Arnold","year":"2005","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.jpsychires.2020.02.022_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1089\/cap.2013.0146","article-title":"A double-blind efficacy and safety study of duloxetine flexible dosing in children and adolescents with major depressive disorder","volume":"24","author":"Atkinson","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.02.022_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248414531852","article-title":"Food and drug administration regulation of drugs that raise blood pressure","volume":"20","author":"Blankfield","year":"2015","journal-title":"J. Cardiovasc. Pharmacol. Therapeut."},{"issue":"9","key":"10.1016\/j.jpsychires.2020.02.022_bib6","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1038\/sj.npp.1300209","article-title":"Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study","volume":"28","author":"Chalon","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychires.2020.02.022_bib7","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2147\/IJGM.S3979","article-title":"A six-month double-blind, placebo-controlled, randomized clinical trial of duloxetine for the treatment of fibromyalgia","volume":"1","author":"Chappell","year":"2008","journal-title":"Int. J. Gen. Med."},{"issue":"6","key":"10.1016\/j.jpsychires.2020.02.022_bib8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care: the Framingham Heart Study","volume":"117","author":"D'Agostino","year":"2008","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.jpsychires.2020.02.022_bib9","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.euroneuro.2004.01.002","article-title":"Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"14","author":"Detke","year":"2004","journal-title":"Eur. Neuropsychopharmacol"},{"issue":"4","key":"10.1016\/j.jpsychires.2020.02.022_bib10","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1089\/cap.2013.0096","article-title":"A double-blind efficacy and safety study of duloxetine fixed doses in children and adolescents with major depressive disorder","volume":"24","author":"Emslie","year":"2014","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"7005","key":"10.1016\/j.jpsychires.2020.02.022_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1136\/bmj.311.7005.619","article-title":"Probability of adverse events that have not yet occurred: a statistical reminder","volume":"311","author":"Eypasch","year":"1995","journal-title":"BMJ"},{"issue":"Suppl. 1","key":"10.1016\/j.jpsychires.2020.02.022_bib12","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1097\/01.psy.0000162253.07959.db","article-title":"Reflections on depression as a cardiac risk factor","volume":"67","author":"Frasure-Smith","year":"2005","journal-title":"Psychosom. Med."},{"issue":"10","key":"10.1016\/j.jpsychires.2020.02.022_bib13","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1185\/03007995.2011.609539","article-title":"A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms","volume":"27","author":"Gaynor","year":"2011","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.jpsychires.2020.02.022_bib14","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.jcp.0000132448.65972.d9","article-title":"Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine","volume":"24","author":"Goldstein","year":"2004","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2020.02.022_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.psychres.2018.07.044","article-title":"Antidepressants-related cardiovascular adverse events using the adverse event reporting system","volume":"268","author":"Lee","year":"2018","journal-title":"Psychiatr. Res."},{"issue":"3","key":"10.1016\/j.jpsychires.2020.02.022_bib16","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/JCP.0000000000000701","article-title":"Cerebrovascular, cardiovascular, and mortality events in new users of selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors: a propensity score-matched population-based study","volume":"37","author":"Leong","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"issue":"9349","key":"10.1016\/j.jpsychires.2020.02.022_bib17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jpsychires.2020.02.022_bib18","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1161\/CIRCULATIONAHA.106.176158","article-title":"Diet and lifestyle recommendations revision 2006: a scientific statement from the American heart association nutrition committee","volume":"114","author":"Lichtenstein","year":"2006","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.jpsychires.2020.02.022_bib19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.genhosppsych.2012.01.018","article-title":"Depression and heart disease in US adults","volume":"34","author":"Niranjan","year":"2012","journal-title":"Gen. Hosp. Psychiatr."},{"issue":"6","key":"10.1016\/j.jpsychires.2020.02.022_bib20","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.eurpsy.2006.03.004","article-title":"Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial","volume":"21","author":"Perahia","year":"2006","journal-title":"Eur. Psychiatr."},{"issue":"5","key":"10.1016\/j.jpsychires.2020.02.022_bib21","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4088\/JCP.08m04756","article-title":"Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial","volume":"70","author":"Perahia","year":"2009","journal-title":"J. Clin. Psychiatr."},{"issue":"20","key":"10.1016\/j.jpsychires.2020.02.022_bib22","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1016\/j.jacc.2018.03.458","article-title":"Psychopharmacology and cardiovascular disease","volume":"71","author":"Pi\u00f1a","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"issue":"5","key":"10.1016\/j.jpsychires.2020.02.022_bib23","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1526-4637.2005.00061.x","article-title":"A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain","volume":"6","author":"Raskin","year":"2005","journal-title":"Pain Med. (Malden, Mass)"},{"issue":"9","key":"10.1016\/j.jpsychires.2020.02.022_bib24","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1111\/j.1468-1331.2009.02648.x","article-title":"A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain","volume":"16","author":"Skljarevski","year":"2009","journal-title":"Eur. J. Neurol."},{"issue":"13","key":"10.1016\/j.jpsychires.2020.02.022_bib25","doi-asserted-by":"crossref","first-page":"E578","DOI":"10.1097\/BRS.0b013e3181d3cef6","article-title":"Efficacy and safety of duloxetine in patients with chronic low back pain","volume":"35","author":"Skljarevski","year":"2010","journal-title":"Spine"},{"key":"10.1016\/j.jpsychires.2020.02.022_bib26","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.jpsychires.2020.02.022_bib27","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaac.2015.01.008","article-title":"A randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder","volume":"54","author":"Strawn","year":"2015","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"issue":"2","key":"10.1016\/j.jpsychires.2020.02.022_bib28","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.jcp.0000155815.44338.95","article-title":"Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine","volume":"25","author":"Thase","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.02.022_bib29","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12969-019-0325-6","article-title":"Efficacy and safety of duloxetine versus placebo in adolescents with juvenile fibromyalgia: results from a randomized controlled trial","volume":"17","author":"Upadhyaya","year":"2019","journal-title":"Pediatr. Rheumatol. Online J."},{"issue":"8","key":"10.1016\/j.jpsychires.2020.02.022_bib30","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/papr.12127","article-title":"A randomized, double-blind, placebo-controlled trial of duloxetine for the treatment of pain in patients with multiple sclerosis","volume":"14","author":"Vollmer","year":"2014","journal-title":"Pain Pract."},{"issue":"5","key":"10.1016\/j.jpsychires.2020.02.022_bib31","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00002018-200730050-00007","article-title":"An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies","volume":"30","author":"Wernicke","year":"2007","journal-title":"Drug Saf."},{"issue":"6","key":"10.1016\/j.jpsychires.2020.02.022_bib32","first-page":"e13","volume":"71","author":"Whelton","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.jpsychires.2020.02.022_bib33","author":"World Heath Organization"},{"issue":"20","key":"10.1016\/j.jpsychires.2020.02.022_bib34","first-page":"3260","article-title":"Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China","volume":"124","author":"Wu","year":"2011","journal-title":"Chin. Med. J. (Engl)."},{"issue":"1","key":"10.1016\/j.jpsychires.2020.02.022_bib35","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/JCP.0b013e31823fb238","article-title":"Treatment with duloxetine in adults and the incidence of cardiovascular events","volume":"32","author":"Xue","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jpsychires.2020.02.022_bib36","doi-asserted-by":"crossref","first-page":"i157","DOI":"10.1136\/bmj.i157","article-title":"PRISMA harms checklist: improving harms reporting in systematic reviews","volume":"352","author":"Zorzela","year":"2016","journal-title":"BMJ"}],"container-title":["Journal of Psychiatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395619313391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022395619313391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T11:15:05Z","timestamp":1758366905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022395619313391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":36,"alternative-id":["S0022395619313391"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychires.2020.02.022","relation":{},"ISSN":["0022-3956"],"issn-type":[{"value":"0022-3956","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Duloxetine and cardiovascular adverse events: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychiatric Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychires.2020.02.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}